Ovid Therapeutics (OVID) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
Meeting commenced at 10:30 A.M. on June 10, 2026, via a virtual platform, with introductions of key executives and auditors.
The agenda included three proposals: election of a director, advisory vote on executive compensation, and ratification of the auditor.
Voting procedures and meeting conduct rules were explained, with polls opened for voting.
Board and executive committee updates
Jeremy M. Levin was nominated for election as Class III director to serve until the 2029 annual meeting.
Shareholder proposals
Three proposals were presented: election of a director, advisory approval of executive compensation, and ratification of KPMG as auditor for 2026.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Ovid Therapeutics
- Advanced pipeline, higher net loss, and strong cash position support future operations.OVID
Q2 2026 - Advancing differentiated neurotherapeutics for epilepsy and psychosis with strong clinical momentum.OVIDCorporate presentation
- Multiple clinical milestones and strong financial runway position the pipeline for significant value creation.OVID7th Annual HCW Neuro Perspectives Hybrid Conference
- Net loss was $17.0M in Q1 2026; cash reserves and funding extend runway into 2029.OVIDQ1 2026
- Advancing novel therapies for seizures and psychosis with strong safety and market potential.OVIDCorporate presentation
- Director election, say-on-pay, auditor ratification, and governance updates headline the 2026 proxy.OVIDProxy filing
- Vote on director election, executive pay, and auditor ratification at the June 2026 meeting.OVIDProxy filing
- Pipeline progress, strong safety, and financing extend cash runway into late 2028 or 2029.OVIDQ4 2025
- OV329 advances with biomarker-driven trials, aiming for safer, differentiated epilepsy therapy.OVIDStatus Update